Given that tau is currently the most reliable predictive, prognostic, and diagnostic CSF marker—rising early in AD and progressing with disease severity—we further assessed whether our classifier proteins might complement tau (34, 44). The gene discussed is MAPT; the disease is Alzheimer disease.